{"id":"https://openalex.org/W2431576889","doi":"https://doi.org/10.3928/23258160-20160601-07","title":"Physician Utilization Patterns for VEGF-Inhibitor Drugs in the 2012 United States Medicare Population: Bevacizumab, Ranibizumab, and Aflibercept","display_name":"Physician Utilization Patterns for VEGF-Inhibitor Drugs in the 2012 United States Medicare Population: Bevacizumab, Ranibizumab, and Aflibercept","publication_year":2016,"publication_date":"2016-06-01","ids":{"openalex":"https://openalex.org/W2431576889","doi":"https://doi.org/10.3928/23258160-20160601-07","mag":"2431576889","pmid":"https://pubmed.ncbi.nlm.nih.gov/27327285"},"language":"en","primary_location":{"id":"doi:10.3928/23258160-20160601-07","doi":"https://doi.org/10.3928/23258160-20160601-07","is_oa":false,"landing_page_url":"https://doi.org/10.3928/23258160-20160601-07","pdf_url":null,"source":{"id":"https://openalex.org/S4210179932","display_name":"Ophthalmic surgery, lasers & imaging retina","issn_l":"1542-8877","issn":["1542-8877","1938-2375","2325-8160","2325-8179"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-d","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-2","vabb-shw"],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Ophthalmic Surgery, Lasers and Imaging Retina","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5019863674","display_name":"Shivani Baisiwala","orcid":"https://orcid.org/0000-0001-5252-9940","observed_orcids":["https://orcid.org/0000-0001-5252-9940"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Shivani Baisiwala","raw_affiliation_strings":[""],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5028634621","display_name":"M. Kate Bundorf","orcid":"https://orcid.org/0000-0002-9824-4868","observed_orcids":["https://orcid.org/0000-0002-9824-4868"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"M. Kate Bundorf","raw_affiliation_strings":[""],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"","institution_ids":[]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5081308768","display_name":"Suzann Pershing","orcid":"https://orcid.org/0000-0002-4622-1859","observed_orcids":["https://orcid.org/0000-0002-4622-1859"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Suzann Pershing","raw_affiliation_strings":[""],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"","institution_ids":[]}]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":1.7716,"has_fulltext":false,"cited_by_count":9,"citation_normalized_percentile":{"value":0.83843032,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":96},"biblio":{"volume":"47","issue":"6","first_page":"555","last_page":"562"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10170","display_name":"Retinal Diseases and Treatments","score":0.9452999830245972,"subfield":{"id":"https://openalex.org/subfields/2731","display_name":"Ophthalmology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10170","display_name":"Retinal Diseases and Treatments","score":0.9452999830245972,"subfield":{"id":"https://openalex.org/subfields/2731","display_name":"Ophthalmology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11792","display_name":"Pharmaceutical Economics and Policy","score":0.00839999970048666,"subfield":{"id":"https://openalex.org/subfields/2002","display_name":"Economics and Econometrics"},"field":{"id":"https://openalex.org/fields/20","display_name":"Economics, Econometrics and Finance"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}},{"id":"https://openalex.org/T11649","display_name":"Pharmaceutical industry and healthcare","score":0.003599999938160181,"subfield":{"id":"https://openalex.org/subfields/3004","display_name":"Pharmacology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/vegf-inhibitors","display_name":"VEGF inhibitors","score":0.9890000224113464},{"id":"https://openalex.org/keywords/bevacizumab","display_name":"bevacizumab","score":0.9909999966621399},{"id":"https://openalex.org/keywords/ranibizumab","display_name":"ranibizumab","score":1.0},{"id":"https://openalex.org/keywords/aflibercept","display_name":"aflibercept","score":1.0},{"id":"https://openalex.org/keywords/intravitreal-injection","display_name":"intravitreal injection","score":0.9409999847412109},{"id":"https://openalex.org/keywords/ophthalmologists","display_name":"ophthalmologists","score":0.7269999980926514},{"id":"https://openalex.org/keywords/medicare-claims-data","display_name":"Medicare claims data","score":0.7379999756813049},{"id":"https://openalex.org/keywords/financial-incentives","display_name":"financial incentives","score":0.7799999713897705},{"id":"https://openalex.org/keywords/anti-vegf-therapy","display_name":"anti-VEGF therapy","score":0.7910000085830688}],"concepts":[{"id":"https://openalex.org/C2781100027","wikidata":"https://www.wikidata.org/wiki/Q414270","display_name":"Ranibizumab","level":4,"score":0.9630957841873169},{"id":"https://openalex.org/C2777802072","wikidata":"https://www.wikidata.org/wiki/Q413299","display_name":"Bevacizumab","level":3,"score":0.9067152738571167},{"id":"https://openalex.org/C2778749236","wikidata":"https://www.wikidata.org/wiki/Q4689286","display_name":"Aflibercept","level":4,"score":0.9056488275527954},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8424299359321594},{"id":"https://openalex.org/C118487528","wikidata":"https://www.wikidata.org/wiki/Q161437","display_name":"Ophthalmology","level":1,"score":0.5315454006195068},{"id":"https://openalex.org/C2908647359","wikidata":"https://www.wikidata.org/wiki/Q2625603","display_name":"Population","level":2,"score":0.49820947647094727},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.3061124384403229},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.155122309923172},{"id":"https://openalex.org/C99454951","wikidata":"https://www.wikidata.org/wiki/Q932068","display_name":"Environmental health","level":1,"score":0.0}],"mesh":[{"descriptor_ui":"D000068258","descriptor_name":"Bevacizumab","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D000068258","descriptor_name":"Bevacizumab","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D000068258","descriptor_name":"Bevacizumab","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D000069579","descriptor_name":"Ranibizumab","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D000069579","descriptor_name":"Ranibizumab","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D000069579","descriptor_name":"Ranibizumab","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D000072163","descriptor_name":"Ophthalmologists","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true},{"descriptor_ui":"D000072163","descriptor_name":"Ophthalmologists","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true},{"descriptor_ui":"D000072163","descriptor_name":"Ophthalmologists","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true},{"descriptor_ui":"D004363","descriptor_name":"Drug Utilization","qualifier_ui":"Q000639","qualifier_name":"trends","is_major_topic":false},{"descriptor_ui":"D004363","descriptor_name":"Drug Utilization","qualifier_ui":"Q000639","qualifier_name":"trends","is_major_topic":false},{"descriptor_ui":"D004363","descriptor_name":"Drug Utilization","qualifier_ui":"Q000639","qualifier_name":"trends","is_major_topic":false},{"descriptor_ui":"D006278","descriptor_name":"Medicare","qualifier_ui":"Q000706","qualifier_name":"statistics & numerical data","is_major_topic":false},{"descriptor_ui":"D006278","descriptor_name":"Medicare","qualifier_ui":"Q000706","qualifier_name":"statistics & numerical data","is_major_topic":false},{"descriptor_ui":"D006278","descriptor_name":"Medicare","qualifier_ui":"Q000706","qualifier_name":"statistics & numerical data","is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D011159","descriptor_name":"Population Surveillance","qualifier_ui":"Q000379","qualifier_name":"methods","is_major_topic":false},{"descriptor_ui":"D011159","descriptor_name":"Population Surveillance","qualifier_ui":"Q000379","qualifier_name":"methods","is_major_topic":false},{"descriptor_ui":"D011159","descriptor_name":"Population Surveillance","qualifier_ui":"Q000379","qualifier_name":"methods","is_major_topic":false},{"descriptor_ui":"D011993","descriptor_name":"Recombinant Fusion Proteins","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D011993","descriptor_name":"Recombinant Fusion Proteins","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D011993","descriptor_name":"Recombinant Fusion Proteins","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D012189","descriptor_name":"Retrospective Studies","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D012189","descriptor_name":"Retrospective Studies","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D012189","descriptor_name":"Retrospective Studies","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D014481","descriptor_name":"United States","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D014481","descriptor_name":"United States","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D014481","descriptor_name":"United States","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D020533","descriptor_name":"Angiogenesis Inhibitors","qualifier_ui":"Q000600","qualifier_name":"supply & distribution","is_major_topic":false},{"descriptor_ui":"D020533","descriptor_name":"Angiogenesis Inhibitors","qualifier_ui":"Q000600","qualifier_name":"supply & distribution","is_major_topic":false},{"descriptor_ui":"D020533","descriptor_name":"Angiogenesis Inhibitors","qualifier_ui":"Q000600","qualifier_name":"supply & distribution","is_major_topic":false},{"descriptor_ui":"D040262","descriptor_name":"Receptors, Vascular Endothelial Growth Factor","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D040262","descriptor_name":"Receptors, Vascular Endothelial Growth Factor","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D040262","descriptor_name":"Receptors, Vascular Endothelial Growth Factor","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D041623","descriptor_name":"Tomography, Optical Coherence","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D041623","descriptor_name":"Tomography, Optical Coherence","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D041623","descriptor_name":"Tomography, Optical Coherence","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D042461","descriptor_name":"Vascular Endothelial Growth Factor A","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":false},{"descriptor_ui":"D042461","descriptor_name":"Vascular Endothelial Growth Factor A","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":false},{"descriptor_ui":"D042461","descriptor_name":"Vascular Endothelial Growth Factor A","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":false},{"descriptor_ui":"D058449","descriptor_name":"Intravitreal Injections","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D058449","descriptor_name":"Intravitreal Injections","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D058449","descriptor_name":"Intravitreal Injections","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.3928/23258160-20160601-07","doi":"https://doi.org/10.3928/23258160-20160601-07","is_oa":false,"landing_page_url":"https://doi.org/10.3928/23258160-20160601-07","pdf_url":null,"source":{"id":"https://openalex.org/S4210179932","display_name":"Ophthalmic surgery, lasers & imaging retina","issn_l":"1542-8877","issn":["1542-8877","1938-2375","2325-8160","2325-8179"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-d","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-2","vabb-shw"],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Ophthalmic Surgery, Lasers and Imaging Retina","raw_type":"journal-article"},{"id":"pmid:27327285","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/27327285","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Ophthalmic surgery, lasers & imaging retina","raw_type":"Journal Article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":0.9763000011444092,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"sustainable_development_goals_aurora":[],"study_designs":[{"id":"https://openalex.org/study-designs/observational-study","display_name":"Observational Study"}],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":12,"referenced_works":["https://openalex.org/W1481978003","https://openalex.org/W1500728559","https://openalex.org/W1968670396","https://openalex.org/W1971964310","https://openalex.org/W2013865180","https://openalex.org/W2015457963","https://openalex.org/W2037978728","https://openalex.org/W2038006647","https://openalex.org/W2057433307","https://openalex.org/W2068334663","https://openalex.org/W2085991296","https://openalex.org/W2146673937"],"related_works":["https://openalex.org/W2464774467","https://openalex.org/W7123429887","https://openalex.org/W2555189142","https://openalex.org/W2949653743","https://openalex.org/W4415955003","https://openalex.org/W2527826246","https://openalex.org/W4391528724","https://openalex.org/W2466725841","https://openalex.org/W2531030576","https://openalex.org/W2138875979"],"abstract_inverted_index":{"BACKGROUND":[0],"AND":[1,17],"OBJECTIVE:":[2],"To":[3],"evaluate":[4],"variation":[5],"in":[6,155],"physician":[7,30],"use":[8,149,164,169],"of":[9,21,39,78,99,140,161],"vascular":[10],"endothelial":[11],"growth":[12],"factor":[13],"(VEGF)":[14],"inhibitors.":[15],"PATIENTS":[16],"METHODS:":[18],"Population-based":[19],"analysis":[20],"comprehensive,":[22],"publicly":[23],"available":[24],"2012":[25],"Medicare":[26],"claims,":[27],"aggregated":[28],"by":[29,63,118],"specialty":[31],"and":[32,54,76],"service":[33],"type":[34],"-":[35],"including":[36],"intravitreal":[37,73],"injections":[38],"bevacizumab":[40,120,130,171],"(Avastin;":[41],"Genentech,":[42],"South":[43,50],"San":[44,51],"Francisco,":[45,52],"CA),":[46,53],"ranibizumab":[47],"(Lucentis;":[48],"Genetech,":[49],"aflibercept":[55],"(Eylea;":[56],"Regeneron,":[57],"Tarrytown,":[58],"NY).":[59],"Physicians":[60],"were":[61,101],"characterized":[62],"total":[64,72,79],"patients":[65,95],"treated,":[66],"proportion":[67,77,139],"treated":[68,93,102],"with":[69,96,103],"each":[70,82,92],"drug,":[71],"injection":[74],"payments,":[75,128],"payments":[80],"for":[81,126,136],"drug.":[83],"RESULTS:":[84],"The":[85],"authors":[86],"identified":[87],"2,869":[88],"ophthalmologists.":[89],"On":[90],"average,":[91],"203":[94],"VEGF-inhibitors,":[97],"75.9%":[98],"which":[100],"bevacizumab.":[104,145],"Using":[105],"all":[106],"three":[107],"agents":[108],"was":[109,131],"the":[110,132],"most":[111,127],"common":[112],"practice":[113],"(1,121":[114],"physicians),":[115],"closely":[116],"followed":[117],"using":[119],"only":[121],"(1,061":[122],"physicians).":[123],"Ranibizumab":[124],"accounted":[125],"but":[129,153,166],"largest":[133],"payment":[134],"source":[135],"a":[137],"sizeable":[138],"physicians":[141],"who":[142],"used":[143],"only/mostly":[144],"CONCLUSION:":[146],"Most":[147],"ophthalmologists":[148,162,167],"multiple":[150],"VEGF":[151],"inhibitors,":[152],"vary":[154],"their":[156],"relative":[157],"use.":[158],"A":[159],"subset":[160],"predominantly":[163],"ranibizumab,":[165],"overall":[168],"more":[170],"despite":[172],"financial":[173],"incentives":[174],"favoring":[175],"ranibizumab.":[176],"[Ophthalmic":[177],"Surg":[178],"Lasers":[179],"Imaging":[180],"Retina.":[181],"2016;47:555-562.].":[182]},"counts_by_year":[{"year":2025,"cited_by_count":1},{"year":2022,"cited_by_count":2},{"year":2021,"cited_by_count":1},{"year":2019,"cited_by_count":1},{"year":2018,"cited_by_count":2},{"year":2017,"cited_by_count":2}],"updated_date":"2026-09-26T08:19:03.415552","created_date":"2016-06-24T00:00:00"}